GlaxoSmithKline plc (GLAXF)
| Previous close | 17.20 |
| Open | 17.99 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 17.99 - 17.99 |
| 52-week range | 13.48 - 23.40 |
| Volume | |
| Avg. volume | 2,104 |
| Market cap | 74.398B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 12.49 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.73 (3.97%) |
| Ex-dividend date | 23 Feb 2023 |
| 1y target est | N/A |
- Business Wire
GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
PHILADELPHIA, March 14, 2023--GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
- Business Wire
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
PHILADELPHIA, December 11, 2022--GSK plc (LSE/NYSE:GSK) today announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR) in myelofibrosis patients previously treated with an approved Janus kinase (JAK) inhibitor. Additionally, new analyses from MOMENTUM showed
- Business Wire
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
LONDON, July 27, 2022--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant.i The approval extends the current indication in the US to include both lupus and ac
